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INTRODUCTION
Adiponectin is an adipose tissue-derived plasma protein that
plays an important role in energy homeostasis regulation,
glucose and lipid metabolism as well as anti-inflammatory
responses in the vascular system (Hu et al., 1996; Ouchi et
al., 2003). Low plasma adiponectin concentrations are
linked to type 2 diabetes (T2D) (Weyer et al., 2001), obe-
sity (Matsuzawa et al., 2003) and coronary heart disease
(CHD) related traits ( Matsuda et al., 2002; Kumada et al.,
2003). Possible mechanisms of adiponectin action in rela-
tion with these inflammatory diseases may include its inhi-
bition of smooth muscle cell proliferation, monocyte adhe-
sion to endothelium, and macrophage uptake of LDL (Chen
et al., 2005).
Adiponectin is a product of the ADIPOQ gene consisting of
three exons that occupies 16 kb on chromosome 3q27. Dur-
ing the last five years, a large number of association studies
have been performed to search for polymorphisms that may
influence metabolic conditions (reviewed in Vasseur et al.
(2006) and Menzaghi et al. (2007)). Even though the num-
ber of polymorphisms and haplotypes are repeatedly associ-
ated with increased or decreased blood adiponectin levels
(Heid et al., 2006; Mackevics et al., 2006; Li et al., 2007;
Kyriakou et al., 2008), association analysis of these SNPs
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Despite the number of recently conducted studies seeking to determine the association between
genetic variants of adiponectin gene and susceptibility to type 2 diabetes (T2D) and increased
body mass index (BMI), the results obtained are often inconsistent. To determine the impact of
common polymorphisms in promoter and coding regions of adiponectin gene on these conditions
in Latvian population, we selected ten SNPs (rs2241767, rs1501299, rs3777261, rs16861210,
rs2241766, rs822396, rs182052, rs17300539, rs16861194, rs266729) based on haploblock struc-
ture and previously reported association studies. The selected SNPs were screened in a study
group of 835 participants from the Genome Data Base of Latvian Population and mainly con-
sisted of patients with T2D and coronary heart disease. None of the individual polymorphisms
were significantly associated with T2D status or BMI when analysed using logistic or linear re-
gression and adjusted for gender, age and other significant covariates. Frequency of rs2241766 T
allele homozygotes however was significantly increased in T2D patients compared to controls
(uncorrected P = 0.007). When analysed with other traits, the rs182052 G allele was found to be
less frequent in patients suffering from myocardial infarction (P = 0.02; OR = 0.76, CI95%
[0.61–0.92]) compared to others. Haplotype analysis revealed significant association of one
haplotype with atrial fibrillation (uncorrected P = 0.01). In summary, we conclude that SNPs in
adiponectin gene are unlikely to represent the risk for T2D, but may be involved in pathogenesis
of CHD in the Latvian population.
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with metabolic and cardiovascular phenotypes give incon-
sistent results across different studies.
The aim of our study was to search for the association be-
tween systematically selected adiponectin gene polymor-
phisms and T2D, body mass index (BMI) as well as CHD
phenotypes in the Latvian population.
MATERIALS AND METHODS
Study subjects. The study was based on data and samples
from the Genome Data Base of Latvian Population, the dis-
ease based biobank. Briefly: participating individuals were
over the age of 18; the health status was recorded, the diag-
noses were based on approved clinical criteria according to
the ICD-10 codes (International Classification of Diseases);
andanthropometric measurements (including weight and
stature), ethnic, social, environmental information and fa-
milial health status was acquired based on a self-reported
questionnaire. Written informed consent was obtained from
all participants. The study group for the subsequent geno-
typing of selected markers was selected from all available
subjects with validated health records and questionnaires in
the biobank. We excluded patients with diseases where out-
come or treatment may influence BMI, including all types
of cancer and diseases of the thyroid gland, but not exclud-
ing patients with cardiovascular diseases. All patients with
T2D were included in the study. In total, 835 subjects were
selected based on these criteria. The study protocol was ap-
proved by the Central Medical Ethics Committee of Latvia.
SNP genotyping. TagSNPs in the adiponectin gene locus
were selected using Haploview software (Barrett et al.,
2005). The SNPs with previously published effect on adipo-
nectin plasma concentration were force included in the
tagSNP set. MALDI TOF-based genotyping platform
(Bruker Daltonics) was used for genotyping all SNPs
(primer sequences and reaction conditions available upon
request). Genotype calling and quality control was per-
formed using GenoTools software (Bruker Daltonics).
Statistical analysis. Statistical analyses were performed
with the PLINK 1.06 software (http://pngu.mgh.har-
vard.edu/purcell/plink/) (Purcell et al., 2007). In contrast to
the natural BMI values, the logarithmically transformed
BMI values displayed normal distribution and were further
used for all quantitative analyses. Linear regression was ap-
plied to examine the association between tagSNPs and
log-BMI adjusting for age and gender. The allelic associa-
tion test (additive model), dominant and recessive model
analysis was performed using the exact Fisher’s test. Logis-
tic regression analysis adjusting for age and those factors
that showed significant association with trait under multi-
variate logistic regression analysis were used for dichoto-
mous trait analysis. Bonferroni correction was used to ad-
just for multiple testing. The permutation test was
performed using label-swapping between SNP and trait con-
dition or logBMI values but leaving intact correlation with
other covariates. 10,000 permutations were performed for
each analysis and corrected (EMP2) P-values were used.
These values are corrected based on calculation of the pro-
portion of permutations in which any of the test statistics
exceeds the particular observed statistic and are more strin-
gent then uncorrected P-values. Odds ratios (OR) and CI
(95%) values were obtained from logistic regression analy-
sis (Exp(B) value), unadjusted mean logBMI values were
calculated and back-transformed for each genotype.
RESULTS
Description of the study group is summarised in Table 1. A
total of ten SNPs in the adiponectin gene locus were geno-
typed in all or part of the participants. SNP information, ob-
served minor allele frequency (MAF) and results of devia-
tion from the Hardy–Weinberg equilibrium test are shown
in Table 2. None of the SNPs were in disagreement with
Hardy-Weinberg equilibrium after correction for multiple
testing. The exact number of successfully genotyped sam-
ples for each SNP in the study group is displayed in Tables
3 and 4, along with the results of association with T2D and
logBMI values, respectively. The SNP rs2241766 was asso-
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T a b l e 1
CHARACTERISTICS OF THE STUDY POPULATION
Parameter Values
Total number of patients
Percentage of females (n)
835
66.7 (557)
Percentage of males (n) 33.3 (278)











Age (years) [mean ± SD] 62.82 ±10.12
BMI [mean ± SD] 28.77 ± 4.71
T a b l e 2














1 rs16861194 188042119 -11422 A G 0.12 0.29
2 rs17300539 188042154 -11387 G A 0.05 0.11
3 rs266729 188042168 -11373 C G 0.28 0.01
4 rs182052 188043476 -10065 G A 0.43 0.35
5 rs16861210 188049192 -4349 G A 0.05 0.27
6 rs822396 188049571 -3970 A G 0.22 1
7 rs2241766 188053586 45 T G 0.05 0.66
8 rs1501299 188053817 276 A C 0.28 1
9 rs2241767 188053890 349 A G 0.05 1
10 rs3774261 188054253 712 G A 0.33 0.93
MAF, minor allele frequency; H-W, Hardy-Weinberg equilibrium
a - according to the NCBI build 36; b - relating to the first position of the
starting codon ATG
ciated with T2D under the recessive model (P = 0.007).
This association remained significant after applying the per-
mutation test (P = 0.049), but lost its significance after cor-
rection for multiple comparisons. Neither of the SNPs
showed any association with T2D when tested using logistic
regression with adjustment for age, sex and BMI under dif-
ferent genetic models (Table 3). Similarly, no difference in
mean values of logBMI was found between genotypes of
any SNP included in analysis (Table 4). We also tested for
association of SNPs with other traits present in our study
group. The results are shown in Figure 1A. Allele A of SNP
rs182052 was less frequent in patients with myocardial in-
farction (39%) compared to controls (45%). This associa-
tion remained significant using multiple logistic regression
analysis adjusting for sex, age, BMI and T2D (P = 0.02; OR
= 0.76, CI95%[0.61–0.92]). The permutation test on this
SNP gave a corrected P value of 0.028. The association did
not retain its significance after Bonferroni correction.
In order to identify possible effects of individual haplotypes
on traits analysed in our study we performed haplotype-
based association. In total, 14 haplotypes were recon-
structed with frequency exceeding 1%. Statistical analysis
of the distribution of probabilistically-inferred set of haplo-
types for different traits is shown in Figure 1B. Haplotype
determined by C and A alleles of rs1501299 and rs3774261,
respectively, and common alleles for other SNPs was more
frequent (26%) in patients with atrial fibrillation compared
to others (14%), P = 0.009.
DISCUSSION
We report in this study the first evaluation of adiponectin
gene polymorphisms in relation with T2D, BMI and cardio-
vascular traits in the Latvian population. First we performed
systematic selection of tagSNPs in ADIPOQ gene locus in
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T a b l e 3
ASSOCIATION OF T2D WITH TEN tagSNPs
SNP Genetic model Number of subjects a P value (Fisher test) P value b (logreg) OR [95% CI]b
T2D Control
rs16861194
additive 3/29/110 10/115/439 0.869 0.778 0.93 [0.57–1.51]
dominant 32/110 125/439 0.924 0.653 0.89 [0.52–1.52]
recessive 3/139 10/554 0.788 0.646 1.49 [0.28–8.08]
rs17300539
additive 0/18/129 4/48/517 0.407 0.377 1.35 [0.7–2.59]
dominant 18/129 52/517 0.258 0.302 1.45 [0.72–2.9]
recessive 0/147 4/565 0.308 - -
rs266729
additive 13/49/72 50/182/271 0.988 0.959 0.99 [0.7–1.4]
dominant 62/72 232/271 0.976 0.986 1.01 [0.64–1.6]
recessive 13/121 50/453 0.934 0.884 0.95 [0.44–2.07]
rs182052
additive 31/57/51 101/270/183 0.95 0.306 0.85 [0.62–1.16]
dominant 88/51 371/183 0.415 0.114 0.69 [0.43–1.1]
recessive 31/108 101/453 0.274 0.983 1.01 [0.58–1.76]
rs16861210
additive 0/18/143 4/59/576 0.804 0.793 1.09 [0.58–2.06]
dominant 18/143 63/576 0.62 0.676 1.16 [0.59–2.26]
recessive 0/161 4/635 0.314 - -
rs822396
additive 9/55/98 30/221/395 0.761 0.518 1.12 [0.79–1.6]
dominant 64/98 251/395 0.879 0.558 1.14 [0.74–1.75]
recessive 9/153 30/616 0.628 0.666 1.23 [0.49–3.14]
rs2241766
additive 2/13/141 0/50/516 0.443 0.314 1.46 [0.7–3.02]
dominant 15/141 50/516 0.763 0.562 1.26 [0.59–2.7]
recessive 2/154 0/566 0.007 - -
rs1501299
additive 13/52/71 47/254/315 0.887 0.545 1.11 [0.78–1.58]
dominant 65/71 301/315 0.821 0.641 1.12 [0.71–1.76]
recessive 13/123 47/569 0.452 0.572 1.26 [0.57–2.81]
rs2241767
additive 1/13/133 0/49/508 0.607 0.924 1.04 [0.47–2.32]
dominant 14/133 49/508 0.784 0.987 1.01 [0.44–2.33]
recessive 1/146 0/557 0.051 - -
rs3774261
additive 5/34/32 61/235/249 0.673 0.815 0.95 [0.62–1.46]
dominant 39/32 296/249 0.922 0.613 1.16 [0.66–2.03]
recessive 5/66 61/484 0.288 0.177 0.47 [0.16–1.42]
Logreg- logistic regression;
a- Distribution of subjects according to genotypes/models: additive 22/12/11; dominant: 12+22/11; recessive 22/12+11 (1, common allele; 2, rare allele)
b- From logistic regression analysis adjusted for gender, age and logBMI
order to ensure maximal capture of all known alleles. In ad-
dition, the forced inclusion of variants shown to influence
plasma adiponectin levels was performed. Estimated minor
allele frequencies (Table 2) of all ten SNPs were higher
than 0.05 in the Latvian population and similar to those re-
ported in the SNP database (www.ncbi.nlm.nih.gov/SNP) or
other publications (Heid et al., 2006). We believe that alto-
gether this ensures the high informativeness of the selected
set of ten markers.
In the present quantitative trait analysis we found no evi-
dence for an association of the tested SNPs with changes in
BMI value. Other studies have previously reported that at
least three of the SNPs also included in this study
(rs266729, rs2241766, rs1501299) might modulate body
weight (reviewed in Vasseur et al. (2006)). However, recent
meta-analysis did not confirm the association of these or
other markers with BMI (Menzaghi et al., 2007). The fail-
ure to identify a stable association between ADIPOQ poly-
morphisms and BMI, despite the repeatedly confirmed rela-
tionship between the levels of plasma adiponectin and BMI
(Yang et al., 2001; Spranger et al., 2003), can be explained
by the variation in genetic background determining the pre-
disposition to obesity. Stratification of the study group
based on common genetic variants influencing body mass
regulation could help to estimate the role of adiponectin
SNPs more precisely.
The only SNP that was significantly associated with T2D in
our study was rs2241766, under the recessive genetic
model. The relatively low frequency of this SNP and ab-
sence of GG homozygotes in the control group, however, do
not allow to precisely determine the relative risk of this
variation. G allele of rs2241766 was found to be associated
with decreased levels of serum adiponectin (Xita et al.,
2005; Li et al., 2007;) as well as T2D (Li et al., 2007). This
result is in agreement with finding, that low plasma levels
are associated with insulin resistance and T2D. It should be
noted, however, that a substantial number of studies failed
to replicate these results (Mackevics et al., 2006; Potapov et
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T a b l e 4
ASSOCIATION OF BMI WITH TEN tagSNPs
SNP Number of subjects Mean [± SE] BMIa P valueb
11/12/22 11 12 22 Additive Dominant Recessive
rs16861194 539/143/13 29.47 [0.23] 29.84 [0.39] 30.23 [1.23] 0.244 0.266 0.536
rs17300539 635/66/4 29.7 [0.22] 29.27 [0.55] 33.22 [2.21] 0.891 0.848 0.175
rs266729 340/227/60 29.79 [0.28] 29.59 [0.32] 29.58 [0.59] 0.427 0.447 0.615
rs182052 232/320/131 29.48 [0.32] 29.57 [0.29] 30.28 [0.41] 0.094 0.358 0.053
rs16861210 706/77/4 29.65 [0.21] 29.71 [0.52] 30.61 [2.24] 0.737 0.757 0.825
rs822396 487/270/38 29.71 [0.24] 29.54 [0.3] 29.45 [0.73] 0.436 0.455 0.670
rs2241766 647/62/2 29.62 [0.21] 29.85 [0.58] 33.15 [3.14] 0.373 0.510 0.137
rs1501299 379/302/60 29.82 [0.26] 29.81 [0.3] 29.47 [0.58] 0.696 0.700 0.836
rs2241767 631/61/1 29.59 [0.22] 30.63 [0.57] 34.78 [4.4] 0.110 0.137 0.256
rs3777261 276/265/66 29.68 [0.34] 29.3 [0.35] 30.09 [0.59] 0.926 0.628 0.328
1, common allele; 2, rare allele
a- BMI values back-transformed from unadjusted mean logBMI values
b- P values from linear regression analysis adjusted for gender and age
Fig. 1. Significance values depicted as negative logarithm of P value from adjusted linear or logistic regression analysis for SNP (A) and haplotype (B) asso-
ciation with all phenotypes.
al., 2008; Szopa et al., 2009). Since previous studies did not
support the recessive model for association of rs2241766
with T2D our result may be as well a false positive finding.
Adiponectin mediates vascular inflammation as an inhibitor
of smooth muscle cell proliferation and macrophage uptake
and has been associated with decreased risk of hypertension
(Iwashima et al., 2004), miocardial infarction (Pischon et
al., 2004) and ischemic stroke (Chen et al., 2005). We,
therefore, tested the association of all SNPs analysed with
presence of different cardiovascular traits. In our study,
rs182052 was associated with decreased risk of miocardial
infarction. Allele A of rs182052 was previously associated
with a decreased adiponectin serum level (Heid et al., 2006;
Kyriakou et al., 2008) and, thus, would be expected to have
negative effect on cardiovascular functions which is oppo-
site to our finding. Nevertheless, Hegener et al. (2006) re-
ported a decreased risk of ischemic stroke for carriers of
this allele. One of the imputed haplotypes was found to be
more frequent in another heart disease trait, atrial fibrilla-
tion. To our knowledge this is the first report of genetic
variants of adiponectin associated with this trait. The two
SNPs, rs1501299 and rs3774261, determining this haplo-
type, have been associated with increased adiponectin level
(Heid et al., 2006; Kyriakou et al., 2008). Interestingly,
plasma adiponectin is higher in patients with persistent
atrial fibrillation (Shimano et al., 2008), which is in oppo-
site to the general tendency of a high adiponectin level be-
ing protective to most of the CHD-related pathogeneses.
Similarly, high blood adiponectin was found to be a predic-
tor for mortality in heart failure (Chang et al., 2009). It has
been speculated that this could be explained with lower sen-
sitivity of adiponectin receptors in atrial fibrillation result-
ing in increased adiponectin secretion (Shimano et al.,
2008). In general, however, the situation with CHD and
adiponectin polymorphisms is similar to obesity and T2D,
where associations found in some studies can not be consis-
tently replicated in other studies (Menzaghi et al., 2007;
Vasseur et al., 2006). It should also be mentioned that none
of the genome wide association studies have identified the
ADIPOQ locus as a candidate for any trait (based on a data-
base search at https://gwas.lifesciencedb.jp and
http://www.genome.gov/gwastudies/).
The main drawback of our study is an increased proportion
of patients with metabolic and cardiovascular traits in study
group. The relatively low number of healthy participants in
the study may have increased Type II error, which would
mask some existing association or decrease the statistical
power. From this respect, additional study with a large con-
trol group is needed to fully evaluate the impact of adipo-
nectin polymorphisms on T2D and BMI in the Latvian
population. An important problem in all studies on a large
number of genetic variations is multiple testing. In our
study, none of the discovered associations retained its sig-
nificance (P < 0.05) after applying the Bonferroni test. It
has been suggested, however, that study-wide adjustments
are not appropriate in the context of genetic association
analysis and that permutation based significance testing can
be used instead. All associations found in this study re-
mained significant after the permutation test.
In summary, although adiponectin plasma levels are linked
with many metabolic traits, our study does not provide
strong support for the hypothesis that SNPs in the ADIPOQ
locus play an important role in development of T2D, obe-
sity and CHD.
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ADIPONEKTÎNA GÇNA LOKUSA ASOCIÂCIJAS ANALÎZE SAISTÎBÂ AR OTRÂ TIPA DIABÇTU, ÍERMEÒA MASAS
INDEKSU UN KARDIOVASKULÂRÂM PAZÎMÇM LATVIJAS POPULÂCIJÂ
Neraugoties uz daudzajiem adiponektîna gçna variantu asociâcijas pçtîjumiem saistîbâ ar otrâ tipa diabçtu (T2D) un paaugstinâtu íermeòa
masas indeksu (ÍMI), lîdz ðim iegûtie rezultâti bieþi ir pretrunîgi. Lai noskaidrotu adiponektîna gçna promotera un kodçjoðâ rajona bieþi
sastopamo polimorfismu ietekmi uz ðîm pazîmçm Latvijas populâcijâ, balstoties uz haplobloku struktûru un iepriekð zinâmiem asociâcijas
pçtîjumiem, tika izvçlçti desmit SNP (rs2241767, rs1501299, rs3777261, rs16861210, rs2241766, rs822396, rs182052, rs17300539,
rs16861194, rs266729). Izvçlçtie SNP tika genotipçti pçtîjuma grupâ, kas sastâvçja no 835 Valsts iedzîvotâju genoma datu bâzes gçnu
donoriem. Ðajâ grupâ bija pârsvarâ no T2D un koronârâs sirds slimîbas (KSS) pacienti. Neviens no individuâliem polimorfismiem nebija
bûtiski asociçts ar T2D vai ÍMI, lietojot daudzfaktoru loìistiskâs vai lineârâs regresijas analîzes un koriìçjot rezultâtus pçc dzimuma,
vecuma un citiem bûtiskiem lîdzfaktoriem. Tomçr tika atrasts, ka rs2241766 T alçles homozigotu frekvence T2D pacientu vidû bija bûtiski
lielâka nekâ kontroles grupâ (nekoriìçta P = 0.007). Analizçjot saistîbâ ar citâm pazîmçm, rs182052 G alçle tika bieþâk atrasta pacientiem
ar miokarda infarktu (P = 0.02; OR = 0.76; CI95%[0.61–0.92]), salîdzinot ar pârçjo pçtîjuma grupu. Haplotipu analîze atklâja viena
haplotipa bûtisku asociâciju ar mirdzaritmiju (nekoriìçta P = 0.01). Kopumâ var secinât, ka adiponektîna gçna polimorfismi nav uzskatâmi
par bûtiskiem T2D riska faktoriem, bet varçtu bût iesaistîti koronârâs sirds slimîbas patoìençzç Latvijas populâcijâ.
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